Clinical Trial Update: Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating everolimus with alemtuzumab in recurrent chronic lymphocytic leukemia or small lymphocytic lymphoma has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Everolimus (everolimus)

Snippet

Sponsor: Mayo Clinic | Conditions: Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-12-12